Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$25.45 +2.5%	$22.52	$13.40 ▼ $25.88	$4.19B	0.7	1.68 million shs	3.65 million shs
ACLX Arcellx	$72.52 +4.9%	$67.81	$47.86 ▼ $107.37	$3.83B	0.28	479,617 shs	490,724 shs
BEAM Beam Therapeutics	$16.86 -1.8%	$18.86	$13.52 ▼ $35.25	$1.74B	2.22	2.30 million shs	2.79 million shs
VERV Verve Therapeutics	$11.13	$10.22	$2.86 ▼ $11.40	$992.13M	2.23	3.94 million shs	N/A

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.89%	+3.24%	+18.30%	+44.30%	+58.80%
ACLX Arcellx	-1.99%	-4.13%	+0.17%	+18.63%	+17.02%
BEAM Beam Therapeutics	-2.55%	-10.20%	-18.86%	-4.88%	-29.80%
VERV Verve Therapeutics	0.00%	0.00%	+0.91%	+167.55%	+123.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.9455 of 5 stars	3.3	3.0	2.1	4.2	2.5
ACLX Arcellx	2.6098 of 5 stars	3.6	2.0	3.2	2.5	0.0
BEAM Beam Therapeutics	2.5737 of 5 stars	3.5	1.0	2.9	2.5	0.6
VERV Verve Therapeutics	2.9263 of 5 stars	4.2	4.0	0.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.61	Moderate Buy	$28.88	13.46% Upside
ACLX Arcellx	3.13	Buy	$114.31	57.62% Upside
BEAM Beam Therapeutics	3.07	Buy	$48.45	187.39% Upside
VERV Verve Therapeutics	2.33	Hold	$14.57	30.92% Upside

Current Analyst Ratings Breakdown

Latest VERV, BEAM, ACAD, and ACLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$32.00 ➝ $36.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	ACAD ACADIA Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$15.00 ➝ $17.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
8/7/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$37.00 ➝ $38.00
8/6/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $21.00
8/4/2025	ACLX Arcellx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/31/2025	ACLX Arcellx	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$93.00 ➝ $133.00
7/24/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $34.00
7/21/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	4.48	$0.73 per share	34.90	$4.40 per share	5.78
ACLX Arcellx	$107.94M	37.03	N/A	N/A	$8.41 per share	8.62
BEAM Beam Therapeutics	$63.52M	26.85	N/A	N/A	$8.86 per share	1.90
VERV Verve Therapeutics	$32.33M	30.69	N/A	N/A	$5.83 per share	1.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.33	19.14	33.49	6.72	21.80%	14.69%	9.41%	N/A
ACLX Arcellx	-$107.35M	-$3.42	N/A	N/A	N/A	-329.93%	-43.04%	-27.41%	8/14/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	N/A
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	8/14/2025 (Estimated)

Latest VERV, BEAM, ACAD, and ACLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	VERV Verve Therapeutics	-$0.70	N/A	N/A	N/A	$4.26 million	N/A
8/7/2025	Q2 2025	ACLX Arcellx	-$1.03	-$0.94	+$0.09	-$0.94	$16.76 million	$7.55 million
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	$0.16	+$0.02	$0.16	$263.07 million	$264.57 million
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million
5/14/2025	Q1 2025	VERV Verve Therapeutics	-$0.71	-$0.35	+$0.36	-$0.35	$7.13 million	$32.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.91	2.83
ACLX Arcellx	N/A	3.81	3.81
BEAM Beam Therapeutics	N/A	6.75	6.75
VERV Verve Therapeutics	N/A	9.84	9.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ACLX Arcellx	96.03%
BEAM Beam Therapeutics	99.68%
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	28.30%
ACLX Arcellx	8.35%
BEAM Beam Therapeutics	3.50%
VERV Verve Therapeutics	19.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	168.71 million	120.97 million	Optionable
ACLX Arcellx	80	55.11 million	50.51 million	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
VERV Verve Therapeutics	110	89.14 million	71.94 million	Optionable

VERV, BEAM, ACAD, and ACLX Headlines

Recent News About These Companies

Canaccord Genuity Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

August 9 at 12:39 PM | theglobeandmail.com

Verve Therapeutics Announces Merger and Nasdaq Delisting

August 3, 2025 | theglobeandmail.com

GSA Capital Partners LLP Buys 78,768 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

August 2, 2025 | marketbeat.com

Gene Therapy Companies Set Sights on Cardiovascular Disease

August 1, 2025 | genengnews.comG

Y Intercept Hong Kong Ltd Takes Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

July 31, 2025 | marketbeat.com

Cwm LLC Purchases 24,841 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

July 30, 2025 | marketbeat.com

Cerity Partners LLC Invests $110,000 in Verve Therapeutics, Inc. (NASDAQ:VERV)

July 30, 2025 | marketbeat.com

Verve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102

July 29, 2025 | msn.com

Eli Lilly and Company: Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

July 26, 2025 | finanznachrichten.de

Verve Therapeutics (NASDAQ:VERV) Upgraded to "Hold" at Wall Street Zen

July 26, 2025 | marketbeat.com

Eli Lilly completes acquisition of Verve Therapeutics

July 25, 2025 | msn.com

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

July 25, 2025 | prnewswire.com

Lilly and Verve announce expiration of Verve tender offer

July 24, 2025 | prnewswire.com

Penn CRISPR science is the foundation for a gene-editing heart disease treatment under Eli Lilly

July 24, 2025 | msn.com

Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition

July 24, 2025 | finance.yahoo.com

3 Bullish Biotech Stocks With Explosive Growth Trends

...

July 21, 2025 | marketbeat.com

Lilly’s $1 billion CRISPR bet: what Verve means for gene editing

July 16, 2025 | thepharmaletter.comT

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (VERV)

...

July 15, 2025 | marketbeat.com

Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.

July 14, 2025 | msn.com

Biotech Stocks Are Ready to Rebound. 3 to Watch Now.

July 14, 2025 | msn.com

Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.

July 13, 2025 | hindustantimes.comH

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VERV, BEAM, ACAD, and ACLX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$25.45 +0.63 (+2.54%)

Closing price 04:00 PM Eastern

Extended Trading

$25.60 +0.15 (+0.57%)

As of 07:53 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Arcellx NASDAQ:ACLX

$72.52 +3.42 (+4.95%)

Closing price 04:00 PM Eastern

Extended Trading

$72.64 +0.13 (+0.17%)

As of 04:38 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Beam Therapeutics NASDAQ:BEAM

$16.86 -0.31 (-1.81%)

Closing price 04:00 PM Eastern

Extended Trading

$16.91 +0.05 (+0.30%)

As of 07:59 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Verve Therapeutics NASDAQ:VERV

$11.13 0.00 (0.00%)

As of 07/25/2025

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time